Volition Announces the Appointment of New Distributor for Nu.Q® Discover
Rhea-AI Summary
Volition (NYSE AMERICAN: VNRX) appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for Nu.Q® Discover assays in Japan on Feb 10, 2026.
The company serves close to 100 clients, reported substantial 2025 revenue growth for Nu.Q® Discover, cited a ~$1 billion Total Accessible Market, and listed several 2025 commercial and clinical milestones.
Positive
- Appointment of MBL expands Japan distribution channel
- Serving close to 100 clients worldwide
- Cited ~$1 billion Total Accessible Market for companion diagnostics
- Reported substantial 2025 revenue growth for Nu.Q® Discover
- Multiple 2025 milestones: first commercial sale and pharma agreement
Negative
- Distributor relationship is non-exclusive in Japan
- No current diagnostic regulatory approval in Japan documented
- Revenue growth described as substantial without quantified metrics
News Market Reaction
On the day this news was published, VNRX declined 3.05%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $976K from the company's valuation, bringing the market cap to $31M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows no peers in active momentum, and peer price changes are mixed, indicating this move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Listing compliance notice | Negative | +2.7% | NYSE American non‑compliance notice and requirement to submit a remediation plan. |
| Feb 04 | Clinical data symposium | Positive | -4.5% | HS clinical data for Nu.Q® NETs and highlighting a <b>$3.8 billion</b> TAM. |
| Jan 30 | Reimbursement submission | Positive | +13.5% | Preparation of French reimbursement dossier for Nu.Q® Cancer assays. |
| Jan 27 | New indication data | Positive | -0.2% | Study supporting Nu.Q® NETs use in HS with CE‑Marked test and large TAM. |
| Jan 20 | Vet test expansion | Positive | +8.4% | New lab partnerships extending Nu.Q® Vet Cancer test access in US and Asia. |
Recent VNRX news often shows mixed alignment: several positive commercial/clinical updates saw divergent price reactions, while some regulatory or access milestones aligned with upside moves.
Over recent months, Volition announced multiple Nu.Q®-related milestones. These include HS data and commercialization for Nu.Q® NETs with a cited $3.8 billion TAM, new Nu.Q® Vet Cancer test distribution with a $100–150 million TAM range, and preparation of French reimbursement for Nu.Q® Cancer assays. The latest non‑compliance notice from NYSE American added listing risk. Today’s distributor appointment for Nu.Q® Discover in Japan extends the global reach theme seen in earlier vet and HS initiatives.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-02-09 registers 17,968,090 existing and potential shares for resale by current investors. The company will not receive proceeds from these sales, but the structure could create share overhang if large blocks are sold.
Market Pulse Summary
This announcement extends Volition’s Nu.Q® Discover reach by appointing MBL as a non-exclusive distributor in Japan, adding to a base of close to 100 clients and targeting a companion diagnostics TAM just under $1 billion. It complements prior clinical and commercialization milestones across HS, cancer, and veterinary indications. Investors may monitor how many Japanese research and pharma customers adopt the assays, any resulting clinical data, and how this interacts with existing resale overhang of 17,968,090 shares.
Key Terms
companion diagnostics medical
pharmacodynamic biomarkers medical
neutrophil extracellular traps medical
longitudinal phase 1/2b study medical
AI-generated analysis. Not financial advice.
Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented:
"We are delighted to be working with MBL, a leading provider of clinical research tools in
"Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug development across multiple therapeutic areas. Some of these pharmaceutical companies have progressed to late stage clinical trials using our assays as pharmacodynamic biomarkers.
"We estimate the Total Accessible Market for relevant companion diagnostics to be a little under
"We are excited to continue to expand our collaborator network and extend the access to our nucleosome-based biomarkers to drug developers and researchers through this agreement with MBL.
"We believe that this collaboration will generate interest and data from using our Nu.Q® assays in research, which may lay the foundation for a possible future regulatory application for diagnostic status in
In 2025, Volition announced several "firsts" for its Nu.Q® Discover pillar:
- The first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps ("NETs") activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other NETs-related disease.
- The first agreement with a leading pharmaceutical company to utilize Volition's Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study, the first in-human clinical study.
- A co-marketing agreement with Hologic Diagenode, which has a large client base and international reach, providing tools to biotech and pharma companies and also to academic and government organizations.
[1] Data on File: Volition TAM Model
About Nu.Q® Discover
Volition's Nu.Q® Discover program enables drug developers and scientists access to a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market ready.
Nu.Q® Discover is built on proprietary nucleosome quantification technology. It is a valuable research tool for R&D professionals working within the field of pharmaco-epigenetics, studying the epigenetic basis for variation in response to drugs.
About Medical & Biological Laboratories Co., Ltd
MBL was established in 1969 as the first antibody manufacturer in
In the IVD business, they develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases etc. Particularly in the field of autoantibody diagnosis, they are expanding their product lineup as a leading manufacturer in
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-announces-the-appointment-of-new-distributor-for-nuq-discover-302683619.html
SOURCE VolitionRx Limited
FAQ
What did Volition (VNRX) announce on February 10, 2026 about Japan distribution?
How many clients does Volition say use Nu.Q® Discover and what does that mean for VNRX?
What market size did Volition (VNRX) estimate for companion diagnostics related to Nu.Q® Discover?
Did Volition (VNRX) report financial or clinical progress for Nu.Q® Discover in 2025?
Does the MBL distribution deal give Volition diagnostic approval in Japan?
